Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Catalyst

Newcastle innovation centre The Catalyst at full capacity after two years

The centre is part of the Newcastle Helix development, which aims to bring together firms in a number of leading edge scientific sectors

Birmingham Post

Crunch time for calculating farming emissions

Crunch time for calculating farming emissions

Agricultural businesses need not worry about their initial emissions result being held against them, according to industry leaders

Co-Founders programme awards 10 startups £10,000 each to develop product ideas

Co-Founders programme awards 10 startups £10,000 each to develop product ideas

The teams will now go on to Co-Founders+ where they'll be given mentors and specialists to accelerate their ideas

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Northern Ireland science hub Catalyst announces finalists for INVENT start-up competition

The winner of the influential competition will take home £25,000

Birmingham Post

Open-source history: How NZ led a global e-learning revolution

Nearly 20 years ago, Aotearoa – and Catalyst – were at the forefront of an e-learning revolution. Now, with the creation of Te Pūkenga, there's a chance to do it again, writes Don Christie

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

Why Catalyst Biosciences Shares Are Skyrocketing Today

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

North East firms' role in £5.6m ageing programme helping people live longer and happier lives

North East firms' role in £5.6m ageing programme helping people live longer and happier lives

A scheme spearheaded by Newcastle's National Centre for Ageing and the North of Tyne Combined Authority launches to businesses on May 25

Birmingham Post

6 Best-Performing Robinhood Stocks Of 2022

6 Best-Performing Robinhood Stocks Of 2022

The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year, dropping 43.3%.

How much tuna can I eat in a week? The science of mercury poisoning explained

How much tuna can I eat in a week? The science of mercury poisoning explained

Most forms of mercury are potentially very toxic to humans. Eating large amounts of tuna can lead to surprising health problems and issues due to mercury poisoning.

Newcastle hosts international awards showcasing innovations for ageing workforce

Newcastle hosts international awards showcasing innovations for ageing workforce

The National Innovation Centre for Ageing at The Catalyst saw teams from across the world with their ideas to support an ageing global workforce

Birmingham Post

How much tuna can I eat a week before I need to worry about mercury?

How much tuna can I eat a week before I need to worry about mercury?

For as little as A$1 a tin, canned tuna is an excellent, affordable source of protein, polyunsaturated fats and other nutrients. A tin of tuna is significantly cheaper than many types of fresh meat or fish.

The Conversation

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged. Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. Wall Street's estimate for sales…

Are these London’s chicest tree-huggers? Inside Kensington’s eco-wars

Are these London’s chicest tree-huggers? Inside Kensington’s eco-wars

Fashion mavens Olivia von Halle and Daisy Hoppen are among a glossy posse of Kensington residents fighting developers felling trees in the leafy west London suburb. Samuel Fishwick reports

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Energy Transfer

Vertex Pharmaceuticals Incorporated

Robinhood Markets, Inc.

Open University

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

276,796 stories

113,963 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play